Imetelstat Sodium - NCI - National Cancer Institute
Imetelstat sodium works by blocking the activity of an enzyme called telomerase, which is found at high levels in cells that divide rapidly, including cancer cells. Blocking this enzyme keeps cancer cells …
Oncology Drug Reference Sheet: Imetelstat - ons.org
Mar 18, 2025 · In June 2024, imetelstat (Rytelo™) became the first telomerase inhibitor approved by the U.S Food and Drug Administration (FDA). Imetelstat treats low- to intermediate-risk myelodysplastic …
Imetelstat (Rytelo): a promising treatment for adults with lower-risk ...
Treatment with Imetelstat causes cell death, shortens telomeres, and decreases the quantity of cancerous stem and progenitor cells 3. Imetelstat acts especially on those cells with high telomerase …
RYTELO® (imetelstat) HCP Website | RYTELOHCP
RYTELO® (imetelstat) is indicated for treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia.
Imetelstat (Rytelo™) - OncoLink
Jun 16, 2024 · Imetelstat (Rytelo™) is a telomerase inhibitor.How To Take Imetelstat Imetelstat is given intravenously (into a vein). The amount given and schedule are based on your size. You will have …
Rytelo: Uses, Dosage, Side Effects, Warnings - Drugs.com
Jul 16, 2024 · Rytelo (imetelstat) is an injectable telomerase inhibitor that may be used to treat adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia.
FDA approves imetelstat for low- to intermediate-1 risk myelodysplasti
On June 6, 2024, the Food and Drug Administration approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk ...
Geron Announces FDA Approval of RYTELO™ (imetelstat), a ... - Geron …
Jun 6, 2024 · About Geron Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO™ …
Imetelstat: a new addition to the therapeutic landscape of lower-risk ...
Jan 30, 2025 · Imetelstat is an oligonucleotide telomerase inhibitor recently approved by the US Food and Drug Administration for adults with lower-risk myelodysplasia wh
Imetelstat: First Approval | Drugs - Springer
Aug 20, 2024 · Imetelstat (RYTELO™), an oligonucleotide telomerase inhibitor, is being developed by Geron Corporation for the treatment of myeloid hematologic malignancies. In June 2024, imetelstat …